PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
90.50%
EBIT growth of 90.50% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
74.50%
Operating income growth of 74.50% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
91.74%
Net income growth of 91.74% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
91.71%
EPS growth of 91.71% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
91.71%
Diluted EPS growth of 91.71% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.51%
OCF growth of 55.51% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
55.51%
FCF growth of 55.51% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-103253.49%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-39279.54%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-22130.85%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-247692.89%
Negative 10Y net income/share CAGR vs. Healthcare median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-3218.28%
Negative 5Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-4231.04%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
4781.98%
Equity/share CAGR of 4781.98% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
636.42%
5Y equity/share CAGR of 636.42% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
374.63%
3Y equity/share CAGR of 374.63% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-42.01%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-51.92%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-46.67%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-6.56%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-79.23%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.